DPP4 and type 2 diabetes mellitus: A meta-analysis of 28 trials showed 40% reduction in fracture risk with the treatment of DPP4 inhibitors (11,880 T2D) compared to placebo or other treatments (9,175 T2D) in a duration of 24 weeks (49).